References:
1. Reich K, et al. Br J Dermatol 2021;185(6):1146–1159. 2. Blauvelt A, et al. J Am Acad Dermatol 2021;S0190–9622:0281–4. 3. Griffiths CEM, et al. Presented at the 16th Annual Coastal Dermatology Symposium. 15–16 October 2020.
4. TREMFYA^® (guselkumab) 100 mg solution for injection in pre-filled pen. Summary of Product Characteristics.

Indications:
TREMFYA^® is indicated in the treatment of active psoriatic arthritis (PsA) in adult patients, alone or in combination with methotrexate,
who have had an inadequate response or have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.⁴

TREMFYA^® is indicated for the treatment of moderate-to-severe plaque psoriasis (PsO) in adults who are candidates for systemic therapy.⁴

Footnote:
*Sustained improvements in psoriasis disease severity (as measured by PASI 90 and PASI 100 scores).³

Abbreviations:
JJMC, Johnson & Johnson Medical Cloud; PASI, Psoriasis Area and Severity Index; PsO, psoriasis.

Click here for prescribing information and information about this product, including adverse reactions, precautions, contraindications
and methods of use. Prescribers are recommended to consult the summary of product characteristics before prescribing.

Intended for UK healthcare professionals only.

This advert has been organised and funded by Johnson & Johnson.
CP-534108 | September 2025 © Janssen-Cilag Limited 2025